6287-57-6

Usage

Uses

Used in Pharmaceutical Industry:
8-(ethylsulfanyl)-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione is used as a respiratory stimulant for the treatment of conditions such as asthma and chronic obstructive pulmonary disease (COPD). It operates by relaxing the smooth muscles in the airways, which in turn improves breathing for patients suffering from these respiratory ailments.
Used in Medical Treatments:
As a central nervous system stimulant, 8-(ethylsulfanyl)-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione is utilized in medical treatments where respiratory function needs enhancement. It is often administered in the form of tablets or as a solution for injection to ensure effective delivery to the patient.

Upstream product

• 4921-49-7 8-chlorocaffeine 
• 75-08-1 ethanethiol 
• 110-81-6 Diethyl disulfide 
• 58-08-2 3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione 
• 85-18-7 8-chlorotheophylline 
• 1790-74-5 8-mercapto-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione 
• 75-03-6 ethyl iodide 
• 77-78-1 dimethyl sulfate 
• 64-67-5 diethyl sulfate 
• 1790-74-5 1,3,7-trimethyl-8-thio-uric acid 
• 74-96-4 ethyl bromide 
• 10381-82-5 8-bromocaffeine 
• 811-51-8 sodium thioethylate 

Downstream Products

• 99765-17-0 8-(Ethylthio)-3,4,5,7-tetrahydro-1,3,7-trimethyl-syn-10,anti-11-diphenyl-4,5-ethano-1H-purin-2,6-dion 

Relevant academic research and scientific papers

MLKL INHIBITORS

Purine derivatives that inhibit cellular necroptosis and/or human MLKL, pharmaceutical compositions thereof, and methods of treating an MLKL-mediated disorder with an effective amount of the compound or composition. Said MLKL-mediated disorder is pathology associated necroptosis, including ischemia-reperfusion damage, neurodegeneration, and inflammatory diseases such as acute pancreatitis, multiple sclerosis, inflammatory bowel disease, and allergic colitis.

Discovery of a new class of highly potent necroptosis inhibitors targeting the mixed lineage kinase domain-like protein

We report the development of novel Mixed Lineage Kinase Domain-Like protein (MLKL) inhibitors with single nanomolar potency (compound 15 is also named as TC13172). Using the converting biochemistry to chemistry activity-based protein profiling (BTC-ABPP) method, we were able to determine that the inhibitors covalently bind to Cysteine86 (Cys-86) of MLKL. This is the first example of the use of LC-MS/MS to identify the binding site of an MLKL inhibitor. The novel MLKL inhibitors provide powerful tools to study the biological function of MLKL and demonstrate that MLKL should be viewed as a druggable target.

Antioxidant properties of thio-caffeine derivatives: Identification of the newly synthesized 8-[(pyrrolidin-1-ylcarbonothioyl)sulfanyl]caffeine as antioxidant and highly potent cytoprotective agent

A series of nine thio-caffeine analogues were synthesized and characterised by NMR, FT-IR and MS spectroscopic methods. Molecular structures of four of them were determined using single crystal X-ray diffraction methods. The antioxidant properties of all

Copper-catalyzed direct thiolation of xanthines and related heterocycles with disulfides

A novel copper-catalyzed, base-free direct thiolation of xanthines and related heterocycles is described, featuring the use of inexpensive Cu(OAc) 2·H2O as the catalyst, O2 as a clean and cheap oxidant, and easy-to-handle